

RESEARCH PAPER



Up-regulation of *SNHG6* activates *SERPINH1* expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression

Gang Wu^a, Xueming Ju^b, Youyu Wang^c, Zhixi Li^d, and Xianfeng Gan^a

^aDepartment of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; ^bDepartment of Ultrasound, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; ^cDepartment of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China; ^dDepartment of Pediatric Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China

ABSTRACT

We aimed to assess the roles of small nucleolar RNA host gene 6 (*SNHG6*) in hepatocellular carcinoma (HCC) progression, and establish the lncRNA-miRNA-mRNA regulation mechanism for HCC therapy. *SNHG6* is one of the host genes in small nucleolar RNAs (snoRNAs), which make a difference in the development of human cancers. *SERPINH1* is a gene encoding a member of the serpin superfamily of serine proteinase inhibitors with miRNA predicted by TargetScan and DIANA Tools. *SNHG6*, serpin family H member 1 (*SERPINH1*) and miR-139-5p expression levels in HCC tissues and cells were determined by quantitative real-time PCR (qRT-PCR). Migration and invasion of HCC cells were measured by transwell assay. Cell cycle analysis was determined by using flow cytometry. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay and colony formation assay were performed for cell viability analysis. The expression of *SERPINH1* was detected by qRT-PCR and western blot. Dual-luciferase reporter gene assay was conducted to identify the targeted relationship between miR-139-5p and *SNHG6*, as well as *SERPINH1* and miR-139-5p. The positive regulation between *SNHG6* and *SERPINH1* was demonstrated in this study. In contrast, miR-139-5p was significantly down-regulated in HCC cells, the inhibition of miR-139-5p promotes the proliferation of HCC cells, and accelerated the cell cycle of HCC cells. Our study demonstrated the co-expression of *SNHG6* and *SERPINH1* in HCC cells for the first time, which revealed that *SNHG6* could serve as a novel oncogene for the HCC therapy by its regulation.

ARTICLE HISTORY

Received 23 August 2018
Revised 17 February 2019
Accepted 6 April 2019

KEYWORDS

Hepatocellular carcinoma;
SNHG6; *SERPINH1*; miR-139-5p

Introduction


Hepatocellular carcinoma (HCC) is an aggressive malignancy, which is also the leading cause of cancer-related deaths in some African and Asian countries [1,2]. HCC is characterized by high and increasing incidence, low resectability rate, high recurrence after a curative-intent surgery, poor response to medical treatments, and poor prognosis [3]. Current therapies for treating HCC have control over sizes and numbers of the nodules in HCC patients, including locoregional treatments, radiofrequency ablation and chemotherapies [4]. However, these therapies are insufficient in the control of large and numerous nodules. Therefore, it is crucial to develop promising therapies with higher anti-tumor effects, and the novel diagnostic biomarkers identification was

one of the solutions. The exploration of novel molecular targets and regulation mechanism is needed for HCC treatment [4].

Increasing evidences have identified that the essential roles of non-coding RNAs in physiological processes *in vivo* [5]. Non-coding RNAs can be divided into two main groups, long noncoding RNAs (lncRNAs) and short noncoding RNAs (miRNAs). lncRNAs are DNA molecules longer than 200 nucleotides, they currently get high attention in cancer therapies, and the critical role of them in tumorigenesis has been recognized [6]. lncRNAs are highly heterogeneous, they possess a wide range of cellular functions, including chemical RNA modification, alternative splicing control and pre-RNA processing [7]. According to previous studies, it has been studied that the abnormal regulation of

CONTACT Xianfeng Gan  ganxianfeng85@163.com

This article has been republished with minor changes. These changes do not impact the academic content of the article.

 Supplemental data for this article can be accessed [here](#).

© 2019 Informa UK Limited, trading as Taylor & Francis Group

lncRNAs can contribute to the carcinogenesis [8]. Furthermore, previous studies have indicated that lncRNAs can induce the pathogenesis and progression of HCC [9]. SNHG6 is one of lncRNAs, it was located in chromosome 8q13.1 (commonly amplified in HCC) and has found to be up-regulated in HCC tissues [10].

MicroRNAs (miRNAs) are a subset of ncRNAs in length of less than 200 nucleotides [11]. Based on the previous studies that related to human malignancies, miRNAs are reported to mainly regulate gene expression post-transcriptionally [12]. The aberrant expression of miRNAs highly associated with the tumor oncogenesis and metastasis, and miRNAs are critical for metabolism in tumor cells [8]. MiR-139, located on chromosome 11q13.4, is down-regulated in several tumor cells, and its anti-oncogenic activity has been identified in humans [13,14]. What is more, the aberrantly expressed miRNA will suppress the expression of mRNA in normal cells, following by cancer occurrence [15]. Therefore, it is hypothesized that the demonstration of abnormally expressed miR-139-5p in HCC cells is crucial in elucidating molecular targets, contributing to the treatment of HCC patients [16].

SERPINH1 is located at 11q13.5 and encodes heat shock protein 47 (HSP47), which is a 418-amino-acid protein and belongs to the serpin superfamily [17,18]. The overexpression of *SERPINH1* in HCC was presented by Naboulsi *et al.* for the first time [19]. Although the expression of HSP47 in different types of cancer has different effects, in some types of cancer, such as glioblastoma and breast cancer, HSP47 is associated with invasiveness [20]. *SERPINH1* and its protein HSP47 act as potential biomarkers in cancer research [21]. Hence, further exploration of the roles of *SERPINH1* and its upstream factors were needed in HCC progression.

Our study compared the expression of *SNHG6* in HCC tissues with several HCC cells, and the abnormal expression of *SNHG6* was found to be closely related to the development and progression of HCC. Additionally, co-expression of *SNHG6* and *SERPINH1* were determined in this study that *SNHG6* could regulate *SERPINH1* expression by competitively binding miR-139-5p. Therefore, *SNHG6* is expected to serve as a novel biomarker for HCC.

Materials and methods

HCC tissue samples and cell lines preparation

Twelve pairs of HCC tissue samples and adjacent normal tissues were obtained from surgical specimens at Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China after informed consent. After excision, all these surgical specimens were snap-frozen at liquid nitrogen. The protocols used in the present study have been approved by Human Subjects Committee of the Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China.

Normal hepatic cell line HL-7702 and HCC cell lines including HepG2, Hep3b, HLE and Huh-7 were obtained from the cell bank of Type Culture Collection (Chinese Academy of Sciences, Shanghai, China). All the cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) with 10% FBS (Gibco) and incubated at 37°C with 5% CO₂.

Cell transfection

Seventy percent confluent cells were transfected via Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) in line with the standard protocol. All the transfected cells were harvested at days 2. The group of transfected cells was shown as below: (1) negative control (NC) group; (2) si-*SNHG6* group: cells transfected with si-*SNHG6* sequence; (3) pcDNA3.1-*SNHG6* group: cell transfected with over-expression *SNHG6*; (4) miR-139-5p inhibitor (inhibitor) group: Cells were transfected with miR-139-5p inhibitor; (5) miR-139-5p mimics (mimics) group: cells were transfected with chemically modified miR-139-5p mimics; (6) miR-139-5p inhibitor + si-*SNHG6* group: miR-139-5p inhibitor modified cells were transfected with si-*SNHG6* sequences. (7) si-*SERPINH1* group: cells were transfected with si-*SERPINH1* sequences. All the agents were purchased from Fugen Co., Ltd (Shanghai, China).

Animal models

Female BALB/c mice (Guangdong Medical Laboratory Animal Center, Guangzhou, China) at 4 to 6 weeks old was selected as animal models. The average weight of mice was 25 g. They were raised in pathogen-free conditions under the feeding

temperature of about 25°C. Mice in good physical health condition were selected for the experiments. HepG2 cells transfected with miR-139-5p mimics, miR-139-5p inhibitor or miR-139-5p inhibitor+si-SNHG6 were harvested from 6 well plates and suspended at 5×10^6 cells/mL. Then, we subcutaneously injected 100 μ l suspended cells into the armpits of mice. The mice were sacrificed 5 weeks after the injection with visible tumors taken for further analysis. All the experiment procedures were in line with the standard instruction guidelines for the use of laboratory animals and approved by the Animal Care and Use Committee in Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China.

Microarray analysis and target prediction

Gene expression profiles were obtained from Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) with the accession number GSE54238. Twelve normal liver samples and 12 HCC samples were selected for analysis. Differentially expressed lncRNAs and mRNAs were filtered by R version 3.4.1 (<https://www.r-project.org/>) with Limma. The criteria for DEGs were based on $|\text{fold change}| > 2$ combined with adjusted P value less than 0.05 and results were exhibited in heatmaps. The target miRNAs screening and prediction of lncRNA&miRNA/miRNA&mRNA binding sites were carried out using miRcode (<http://www.mircode.org/>) and TargetScan (http://www.targetscan.org/vert_71/) and DIANA Tools (<http://diana.imis.athena-innovation.gr/DianaTools>).

Weighted gene co-expression network analysis (WGCNA)

WGCNA R package was utilized to identify the hub genes of every significant module, and the data was from GSE54238 microarray analysis result. Clusters of highly correlated genes were identified and summarized using the module eigengene or the intramodular hub gene. The adjacency matrix was transferred to the topological overlap matrix (TOM), modules were visualized by heatmap plots of gene-gene connectivity that were shown in TOMplot. To obtain modules with highly co-expressed genes, they were identified by hierarchical clustering, which separated individual

cluster into hub-clusters and formed gene clustering trees. To determine the conservative of modules, we assessed modules by their Z scores. By performing Z summary statistics method, permutation Z scores were obtained to determine whether the module is better than a random sample of genes. Z summary was the summary of individual Z scores (the lower the Z summary, the more the module presentation). We could demonstrate the preservation of connectivity by performing this assay.

Establishment of co-expression network

To construct lncRNAs/mRNAs (hub genes) co-expression networks, "pearson" in "psych" package was applied to determine the correlations among DEGs in the selected hub genes and lncRNAs. The networks were adjusted by "BH". Then, they were graphed using Cytoscape software. In these networks, nodes represented DEGs and the edges represented the existence of co-expression.

Dual luciferase reporter gene assay

The potential binding sites of miR-139-5p were predicted using TargetScan and miRanda websites. The predicted sequence of the miR-139-5p binding site was 3'-UGACAUC-5'. The wild types and mutant seed regions of *SERPINH1* and *SNHG6* were synthesized and cloned into two pET vectors. 5×10^4 cells/well were added in 24-well plates. MiR-139-5p mimic or control mimic, pET-*SERPINH1* 3'UTR-WT vector or pET-*SERPINH1* 3'UTR-MUT vector, pET-*SNHG6* 3'UTR-WT vector or pET-*SNHG6* 3'UTR-MUT vector containing firefly luciferase reporter gene and 3'UTR of *SERPINH1/SNHG6* gene (Promega, Madison, WI) were co-transfected by using Lipofectamine 2000. Forty-eight hours after the transfection, the luciferase activity was measured by Dual Luciferase Reporter Assay System (Promega).

RNA isolation and qRT-PCR

Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription of mRNA and lncRNA was conducted with PrimeScriptTM RT Master Mix Kit (TaKaRa, Osaka, Japan). As for the detection of miRNA, the reverse transcription was performed using miRNA cDNA

Synthesis Kit (ABM, Canada). QRT-PCR was carried out using the SYBR Green PCR Kit (Toyobo) under the standard instrument. Results were analyzed by an iQ5 quantitative RCR system (Bio-Rad, California, USA). β -actin or U6 was served as a control, $2^{-\Delta\Delta CT}$ values were normalized to β -actin levels. Each sample was measured in triplicate. Primers involved in this study were shown in Table 1.

Western blot assay

Total protein was extracted, and protein lysate was then obtained using RIPA buffer (Beyotime, China). The lysate was centrifuged at 14,000 rpm to obtain the supernatant about 20 μ L for western blotting. Initially, protein samples were analyzed with SDS-PAGE then transferred to polyvinylidene difluoride membranes (Sigma, Germany). The membranes were washed with TBST, fixed in 5% BSA buffer, and incubated with primary antibodies: anti-SERPINH1 antibody (1/5000; ab109117; Abcam) and anti- β -actin antibody (1/2000; ab8226; Abcam). The secondary antibody was goat anti-rabbit IgG H&L (1/5000; ab6721; Abcam). Results of the immune reactions were obtained and visualized by using Pierce ECL-plus (Invitrogen, Carlsbad, CA).

Transwell assay

In cell migration assay, tissue culture inserts in 8-mm pore size were placed into the 24-well culture plates, which were separated into the upper and lower chambers (Corning, USA). Subsequently, 1×10^5 cells/well were added into the upper chamber, 600 μ L DMEM (10% FBS) was placed into the lower chamber. Cells that migrated cross the transwell membrane were

fixed in 4% paraformaldehyde and stained with crystal violet 24 h after the incubation under humidified condition. The numbers of migrated cells were counted with a microscope ($\times 100$ magnification). The experiment was performed in triplicate. Cell invasion assay was almost the same as migration, except chambers were wrapped in Matrigel (BD Biosciences, San Jose, CA, USA) for invasion assays.

Cell cycle analysis

The cell cycle analysis was performed as the following description [22]. Briefly, 1×10^6 HepG2 or Hep3b cells were collected and washed with PBS. The cells were stored in the freezer overnight after fixing with 70% pre-chilled ethanol. The cells were stained with propidium iodide (Sigma) after RNaseA treatment and analyzed with flow cytometry (Calibur; Becton Dickinson, Franklin Lakes, USA). The distribution of the cell cycle status was re-analyzed with FlowJo software (FlowJo LLC, Ashland, USA).

RNA immunoprecipitation (RIP) assay

RIP assays were conducted by using EZ-Magna RIP RNA-binding Protein Immunoprecipitation Kit (Millipore, USA) in accordance with standard protocol. HepG2 cells were lysed using RIP lysis buffer, then the cell lysates were incubated with RIP buffer including magnetic beads conjugated to a human anti-Ago2 antibody (Abcam), mouse IgG (Beyotime, China) was served as a control group. The co-precipitated RNAs were isolated using TRIzol reagent (TaKaRa, China), Ago-IPs were detected in triplicate.

Cell viability assay

Total of 1×10^5 cells per well were placed into 96-well plates and inoculated for 12 h before treatment 24 h after cells transfection. The proliferation of HCC cells was analyzed 5 days after the treatment by MTS (Promega, Madison, WI). Twenty microliter of the reaction solution was supplemented into cultured cells and incubated at 37°C for 2 h, and the absorbance of the supernatant was detected at 24 h, 48 h and 72 h. The optical density was detected at 490 nm. Each assay was performed in triplicate.

Table 1. Primer sequences for qRT-PCR.

Genes	Sequences
SERPINH1	F: 5'-CAGAAGTTTCTCGGACGGG-3' R: 5'-GCCTGCCTTTTTCATTCTGGG-3'
MiR-139-5p	F: 5'-TCTACAGTGCACGTGC-3' R: 5'-CAGGGTCCGAGGTATTC-3'
SNHG6	F: 5'-TTAGTCATGCCGGTGTGGTG-3' R: 5'-ACCTATATGCTCAATACATGCCG-3'
U6	F: 5'-GGAGCGAGATCCCTCCAAAAT-3' R: 5'-GGCTGTTGCATACTTCTCATGG-3'
β -actin	F: 5'-CACCATTGGCAATGAGCGGTTCC-3' R: 5'-AGGTCCTTGC GGATGTCCACGT-3'

Colony formation assay

Cells were made into single-cell suspensions with trypsin after transfection and incubated in 24-well plates with a density of 1×10^3 cells per well. Cells were cultured for two weeks under the condition of 37°C with 5% CO₂. 4% paraformaldehyde was prepared to fix cells. Images were captured and the visible colonies were counted using Image J software.

Statistical analysis

All the data was shown as mean value \pm standard deviation (mean \pm SD) in this study. Statistical comparison was conducted by analysis variance, and the analysis was performed using GraphPad Prism 6.0 (GraphPad Software, Inc. San Diego, CA). Statistical comparison between two experimental groups was conducted using Mann–Whitney U test. In addition, Kruskal–Wallis test was used for the comparison among more than two groups with Dunn’s multiple comparison test as a post-hoc test. $P < 0.05$ was considered to be statistically significant.

Results

Expression profiles of mRNAs and lncRNAs in HCC

Fold-change (tumor compared with normal controls) and P value were calculated by normalized expression. By using microarray assays, DEGs were screened out ($FC \geq 2.0$, $P < 0.05$). After microarray analysis, 20 most differentially expressed genes (DEGs) were shown in the heat map (Figure 1a) and *SERPINH1* was obviously up-regulated in HCC cells among these DEGs. Above all, we concluded that the regulation of *SERPINH1* may exert some influences on the occurrence and progression of HCC.

Construction of co-expression modules of HCC

The co-expression module was constructed by using the WGCNA package tool. Based on soft power value was 7, the relevant independence degree of modules was 0.9 (Figure 1b). The power value was used to construct a co-expression module. The results of gene dendrograms showed that there were nine distinct gene co-expression modules in HCC. These distinct modules of co-expressed mRNAs were shown in

different colors (Figure 1c). Branches of gene dendrograms illustrated different groups of genes. The interactions of the nine co-expression modules were visualized in Figure 2a–B. By using MDS plot with two dimensions, the analyzed modules tended to correspond to “fingers”, and the intra-modular hubs were shown in the fingertips. Genes in magenta and yellow modules showed significance in HCC, especially the genes in the magenta module (Figure 2c,d). The flashClust tools package was utilized to analyze the cluster on these modules to obtain the tree, the results were shown in Figure 2e. According to the Z scores of all modules (Figure 2f), only five modules got Z summary < 10 , which suggested that these modules were significantly better than a random sample of genes. All the hub genes corresponding to these five modules were identified in Figure 3a, and *SERPINH1* was the hub gene in the magenta module. Weighted gene co-expression network of the magenta module was illustrated in Figure 3b, and the results showed that the mRNA *SERPINH1* was in the center of the network. In addition, details of weighted gene co-expression network of the magenta module were shown in Supplementary Table S1. Hence, it was determined that *SERPINH1* was highly expressed hub gene in HCC.

Co-expression network between lncRNAs and mRNAs in HCC

Next, we intended to screen an appropriate lncRNA with microarray analysis, differentially expressed lncRNAs were filtered under the condition of $|\log_2 \text{fold change}| > 1$ and $P < 0.05$, and 20 most differentially expressed lncRNAs were shown in the heat map (Figure 3c). Co-expression network was constructed based on hub genes and lncRNAs, which were shown in Figure 3d. Both *SERPINH1* and *SNHG6* were up-regulated in HCC cells, and there was a positive association between them. Using miRCode, TargetScan and DIANA Tools, we analyzed the target miRNAs of *SERPINH1* and *SNHG6* in HCC cells, and the results were shown in the Venn diagram (Figure 3e). As a result, 15 miRNAs that existed possible targeted relationship with mRNAs and lncRNAs were determined. Therefore, miR-139-5p selected for the following studies.




Figure 1. *SERPINH1* was up-regulated in HCC tissues. (a) Heatmap diagram generated by unsupervised clustering analysis with differentially expressed mRNAs in 12 paired HCC tissues and adjacent normal tissues. (b) Log-log plot of whole-network connectivity distribution. The x-axis showed the logarithm of whole network connectivity, y-axis showed the logarithm of the corresponding frequency distribution. On this plot, the distribution approximately followed a straight line, which is referred to an approximately scale-free topology. (c) Hierarchical cluster dendrogram derived from all the differentially expressed genes (DEGs) defined nine modules. Different colors below the diagram represented different modules.

Expression level of *SNHG6* in HCC tissues and cell lines

The expression level of *SNHG6* in HCC samples was significantly higher than in the control group (** $P = 0.0038$, Figure 4a). In addition, *SNHG6* expression level in five cultured cell lines, including the normal liver cell line, HL-7702, and four HCC cell lines (HepG2, Hep3b, HLE, Huh7) was compared. Based on the results of qRT-PCR, the *SNHG6* expression level was up-regulated in all four HCC cell lines, especially

in HepG2 HCC cell line compared with HL-7702 cell line (** $P_{\text{HepG2}} = 0.0093$, $*P_{\text{Hep3b}} = 0.018$, $*P_{\text{HLE}} = 0.030$, $*P_{\text{Huh-7}} = 0.044$, Figure 4b). Besides, the results of QRT-PCR showed that *SNHG6* expression was remarkably down-regulated by si-*SNHG6* (** $P = 0.0022$, ** $P = 0.0049$, Figure 4c), while *SNHG6* expression was increased with transfection of pcDNA3.1-*SNHG6* (** $P = 0.0014$, ** $P = 0.0036$, Figure 4e). MTT assay was performed to assess cell viability activity in different transfection groups, and the




Figure 2. Network visualization plots. (a) Visualization of the gene network using a heat map plot. The heat map depicted the Topological Overlap Matrix (TOM) among all genes in the analysis. Light color represented low overlap and progressively darker red color represents higher overlap. Blocks of dark colors along the diagonal are the modules. The gene dendrogram and module assignment were also shown along the left side and the top. (b) Pairwise scatterplots of module eigengenes and the trait y . (c) Multi-dimensional scaling plot in which modules tend to correspond to “fingers”. Intramodular hubs are in the fingertips. (d) Barplot of mean gene significance across modules. The higher the mean gene significance in a module, the more significantly relative the module is to the clinical trait of interest. (e) Hierarchical clustering dendrogram of module eigengenes. The brown and turquoise, the blue and yellow, the magenta and red are highly related, as evidenced by their low merging height. (f) Corresponding Z summary scores and module size of different modules reflect the preservation of modules.

results exhibited cell viability was conspicuously weakened by si-*SNHG6*, while enhanced by pcDNA3.1-*SNHG6* ($*P = 0.040$, $*P = 0.026$, $*P = 0.019$, $*P = 0.011$; $**P = 0.0031$, $**P = 0.0057$, $*P = 0.019$, $**P = 0.0079$, Figure 4d,f).

MiR-139-5p was significantly up-regulated by si-*SNHG6*, while down-regulated by pcDNA3.1-*SNHG6*. On the contrary, *SERPINH1* was down-regulated in the si-*SNHG6* group and highly expressed in pcDNA3.1-*SNHG6* group




Figure 3. Co-expression network between mRNAs and lncRNAs. (a) The hub genes corresponding to each module were identified, especially *SERPINH1* is the hub gene in the magenta module. (b) PPI of genes in the magenta module, red color one represents the high expression, blue one represented a low expression. (c) Heat map diagram generated by unsupervised clustering analysis with 12 pairs differentially expressed lncRNAs in HCC tissues and adjacent normal tissues. (d) Co-expression of *SNHG6* and *SERPINH1*. Up-regulated mRNA was indicated to pink circle, up-regulated lncRNA was indicated to red Rhombus and down-regulated lncRNA was indicated to light purple Rhombus. (e) 15 miRNAs that possessed possibly targeted relationships with mRNAs and lncRNAs were determined by Venn diagram.

(** $P = 0.0044$, ** $P = 0.0013$, ** $P = 0.0043$, ** $P = 0.0024$; ** $P = 0.0092$, ** $P = 0.0065$, ** $P = 0.0086$, ** $P = 0.0038$, Figure 4g).

Stimulative effects of *SNHG6* on cell migration and invasion in HCC cells

Based on the observation results in the si-*SNHG6* group, colony number in HepG2 and Hep3b cells was significantly decreased compared with si-NC group (** $P = 0.0049$, ** $P = 0.0026$, Figure 5a). Up-regulation of *SNHG6* in HCC cell lines encouraged us to study whether the inhibition of *SNHG6* would suppress HCC migration and invasion. HepG2 and Hep3b cell lines were also selected because they

possessed the highest expression level of *SNHG6* expression among the four HCC cell lines. In cell migration assay, inhibition of *SNHG6* significantly suppressed the numbers of migrating cells in both HepG2 and Hep3b cell lines (* $P = 0.047$, * $P = 0.025$; * $P = 0.040$, * $P = 0.033$, Figure 5b). Cell invasion assay showed the similar results with cell migration assay. To further demonstrate the up-regulation of *SNHG6* in HCC cell lines, the cell cycle was analyzed by flow cytometry, and the results were shown in Figure 5c. We observed that the percentage of G0/G1 of two cell lines showed an increase from si-NC group to si-*SNHG6* group (* $P = 0.038$, * $P = 0.050$), which suggested that the inhibition of *SNHG6* expression can block the cell cycle of HCC cell lines. Overexpression




Figure 4. *SNHG6* was highly expressed in HCC cells. (a) *SNHG6* was significantly higher expressed in HCC tissues compared with adjacent normal tissues, expression levels were calculated from the gene/ β -actin expression ratio (** $P < 0.01$, compared with a normal group). (b) *SNHG6* expression level in one normal liver cell line: HL-7702 and four HCC cell lines: HepG2, Hep3b, HLE and Huh7. (* $P < 0.05$, ** $P < 0.01$, compared with HL-7702 group) (c) QRT-PCR showed *SNHG6* expression levels in HepG2 and Hep3b cell lines were down-regulated by si-*SNHG6*. (** $P < 0.01$, compared with a si-NC group, respectively) (d) Cell viability of two HCC cell lines was analyzed by MTT assay. The inhibition of *SNHG6* can significantly decrease the cell viability compared with the NC group. (* $P < 0.05$, compared with a si-NC group, respectively) (e) QRT-PCR showed *SNHG6* expression levels in HepG2 and Hep3b cell lines were up-regulated by pcDNA3.1-*SNHG6*. (** $P < 0.01$, compared with Vector group, respectively) (f) MTT assay exhibited pcDNA3.1-*SNHG6* can significantly increase the cell viability compared with the vector group. (* $P < 0.05$, ** $P < 0.01$, compared with Vector group, respectively) (g) Down-stream miR-139-5p and *SERPINH1* expressions in different transcription groups were detected by QRT-PCR (** $P < 0.01$, compared with si-NC or Vector group, respectively). Every experiment was performed for 3 times at least.

of *SNHG6* in liver cancer cell lines was conducted. Colony formation assay showed cell proliferation ability was boosted with the over-expression of *SNHG6* (** $P = 0.0057$, ** $P = 0.0009$, Figure 6a). Similarly, cell migration and invasion capability were enhanced by pcDNA3.1-*SNHG6* (** $P = 0.0066$, ** $P = 0.0089$; ** $P =$

0.082, $P = **0.099$, Figure 6b). The percentage of G0/G1 of two cell lines significantly decreased in the pcDNA3.1-*SNHG6* group (* $P = 0.021$, ** $P = 0.010$, Figure 6c). In summary, these results demonstrated that *SNHG6* played a significant role in HCC progression.




Figure 5. Si-SNHG6 inhibited the proliferation and viability of HCC cells. (a) Colony numbers in the si-SNHG6 group and the si-NC group were counted and compared. Knockdown of SNHG6 showed a significant decrease in the number of HCC cells. (** $P < 0.01$, compared with the si-NC group) (b) Migration and invasion rate of HepG2 and Hep3b cells in different transfection groups, the migration cells and invasion cells per field suggest the migration and invasion rate of cells. (* $P < 0.05$, compared with a si-NC group) (c) Flow cytometry analysis of the cell cycle phase distribution. Representative cell cycle analysis (left panel). Results are represented as mean \pm SD (* $P < 0.05$, compared with a si-NC group). Every experiment was performed for 3 times at least.

Targeted relationship between SNHG6 and miR-139-5p

MiR-139-5p was screened out previously by using a Venn diagram. We performed luciferase reporter assay to determine the targeted relationship between miR-139-5p and SNHG6, the binding sites were shown in Figure 7a. After binding to the miR-139-5p by SNHG6, the luciferase activity in SNHG6-wt group was significantly decreased compared with the SNHG6-mut

group (** $P = 0.0028$, Figure 7b). In Figure 7c, as expected, RNAs were significantly more enriched in the Ago-IP fractions of HepG2 cells compared with IgG-IP group (** $P < 0.001$). Besides, miR-139-5p expression levels in HCC tissues and normal tissues were detected by qRT-PCR, the results showed that miR-139-5p expression was significantly decreased in tumor group compared with normal group (** $P = 0.0049$, Figure 7d). We also indicated that the




Figure 6. *SNHG6* promoted the proliferation and viability of HCC cells. (a) Colony numbers in *SNHG6* group and vector group were counted and compared. Overexpression of *SNHG6* showed a significant increase in the number of hepatoma cells. (** $P < 0.01$, compared with Vector group) (b) Migration and invasion rate of HepG2 and Hep3b cells in different transfection groups, the migration cells and invasion cells per field suggested the migration and invasion rate of cells. (** $P < 0.01$, compared with Vector group) (c) Cell cycle analysis showed cell cycle was activated by *SNHG6* ($*P < 0.05$, ** $P < 0.01$, compared with Vector group). Every experiment was performed for 3 times at least.

miR-139-5p expression levels in five cell lines (HepG2, Hep3b, HLE, Huh-7 and the normal cell line HL-7702). It showed that miR-139-5p expression was obviously down-regulated in all four HCC cell lines compared with HL-7702 cell line (** $P = 0.0062$, ** $P = 0.0032$, * $P = 0.020$, ** $P = 0.0048$, Figure 7e).

Inhibition of miR-139-5p can induce the viability and proliferation of HCC cells

QRT-PCR and western blot assays were conducted to verify the direct targeted relationship between *SNHG6* and miR-139-5p (** $P = 0.0014$, ** $P = 0.0052$, Figure 8a). Dy-regulation of miR-139-5p was observed to have no influence on *SNHG6* expression, which




Figure 7. Direct targeted relationship between *SNHG6* and miR-139-5p. (a) The binding sites between wild type *SNHG6*/mutant *SNHG6* and miR-139-5p. (b) Dual luciferase reporter gene assay verified that miR-139-5p could be targeted by *SNHG6*-wt rather than *SNHG6*-mut ($*P < 0.05$, compared with the miR-NC group) (c) MiR-139-5p and *SNHG6* abundance in Ago-RIP fractions as measured by qRT-PCR. (d-e) MiR-139-5p expression was significantly lower in HCC tissues and cell lines compared with adjacent normal tissues and normal liver cell line, respectively. Expression levels were calculated from the gene/ β -actin expression ratio ($*P < 0.05$, $**P < 0.01$, compared with the normal group or HL-7702 group). Every experiment was performed for 3 times at least.

suggested that miR-139-5p could not influence the expression of *SNHG6*. MTT assay was conducted again to analyze cell viability before and after the transfection of miR-139-5p inhibitor/mimics (Figure 8b), the inhibitor transfection group showed significantly higher cell viability compared with NC group ($*P = 0.048$) while the miR-139-5p mimics group showed significantly lower cell viability than NC group ($**P = 0.0035$). In addition, we found that the inhibition of miR-139-5p can significantly increase the number of colonies in HCC cell lines ($*P = 0.042$, $*P = 0.031$, Figure 8c). While this increase can be neutralized by the inhibition of *SNHG6* since colony numbers in Inhibitor+si-*SNHG6* group was found similar to the NC group.

In migration and invasion assay, the inhibition of miR-139-5p can significantly increase both migration and invasion rate of HCC cells, while the miR-139-5p mimics can significantly suppress HCC cells migration and invasion rate ($*P = 0.033$, $*P = 0.016$; $*P = 0.046$, $*P = 0.022$, Figure 8d). The cell cycle of HepG2 and Hep3b cell lines were analyzed by flow cytometry, the inhibition of miR-139-5p can extend the cell cycle of HCC cells because the G0/G1 stage took smaller percentage compared to the cells in NC group ($*P = 0.043$, $*P = 0.029$, Figure 8e). While the inhibition of *SNHG6* can promote the expression of miR-139-5p, the cell cycle of HCC cells in the




Figure 8. miR-139-5p inhibited the proliferation and viability of HCC cells. (a) Relative expression levels of *SNHG6* and miR-139-5p in four transfection groups. (** $P < 0.01$, compared with NC group) (b) Cell viability of HepG2 cells was analyzed by MTT assay. OD value measurement was carried out in four transfection groups under 490 nm. (* $P < 0.05$, ** $P < 0.01$, compared with NC group) (c) Colony numbers in four transfection groups were counted and compared. The inhibition of miR-139-5p showed a significant increase in the number of HCC cells. (* $P < 0.05$, compared with NC group) (d) Migration and invasion rate of HepG2 cells in different transfection groups, the migration cells and invasion cells per field suggested the migration and invasion rate of cells. (* $P < 0.05$, compared with NC group) (e) Cell cycle analysis of the cell cycle phase distribution. Representative cell cycle analysis (left panel). (* $P < 0.05$, compared with NC group). One-way ANOVA was used in Figure 8B. Student's two-tailed *t*-test was used in the remaining figures. Every experiment was performed for 3 times at least.

inhibitor+si-*SNHG6* group was similar to that in the NC group.

miR-139-5p mediated HCC progression via targeting *SERPINH1*

In addition, our further studies showed that the 3'UTR of *SERPINH1* contains a conserved binding site for miR-139-5p, and the binding sites were shown in

Figure 9a. The results of luciferase reporter assay showed that miR-139-5p obviously suppressed the luciferase activity of *SERPINH1*-wt 3'UTR reporter gene (** $P = 0.0076$, Figure 9b). Therefore, these results suggested that *SERPINH1* was the direct target of miR-139-5p in HCC. Both mRNA and protein level of *SERPINH1* were down-regulated by miR-139-5p mimics or instead up-regulated by miR-139-5p inhibitor, and the results were shown in Figure 9c (* $P =$




Figure 9. MiR-139-5p can directly target *SERPINH1*. (a) The binding sites between wild type *SERPINH1*/mutant *SERPINH1* and miR-139-5p. (b) Dual luciferase reporter assay verified that miR-139-5p could target at *SERPINH1*-wt rather than *SERPINH1*-mut (** $P < 0.01$, compared with the miR-NC group) (c) Relative expression level of mRNA *SERPINH1* in miR-139-5p mimics group, miR-139-5p inhibitor group and negative control group. The results were determined by qRT-PCR and western blot. (* $P < 0.05$, compared with NC group) (d) *SERPINH1* was significantly higher expressed in HCC tissues compared with adjacent normal tissues, expression levels were calculated from the gene/ β -actin expression ratio (** $P < 0.01$, compared with a normal group). (e) Relative expression level of *SERPINH1* in normal liver cell line and four HCC cell lines (* $P < 0.05$, ** $P < 0.01$, compared with normal control). Every experiment was performed for 3 times at least.

0.044, * $P = 0.013$). Besides, the results of QRT-PCR and western blot showed that *SERPINH1* was significantly up-regulated in HCC tissues and cells (** $P = 0.0029$; ** $P = 0.0087$, * $P = 0.023$, * $P = 0.050$, * $P = 0.046$, Figure 9d,e). Similar with the results of *SNHG6*, over-expression of *SERPINH1* can promote the cell viability dramatically, while the inhibition of *SERPINH1* can suppress the cell viability dramatically (* $P = 0.038$, * $P = 0.024$; * $P = 0.045$, * $P = 0.041$, Figure 10a,b). However, the addition of miR-139-5p can inhibit

SERPINH1 expression. Cell viability of *SERPINH1*+miR-139-5p group was similar to the NC group. Additionally, the number of colonies in the *SERPINH1* group was almost two times than the number of colonies in the NC group (* $P = 0.045$, * $P = 0.026$, Figure 10c). The results of migration and invasion assay were shown in Figure 10d, the over-expression of *SERPINH1* can induce the migration and invasion of HCC cells significantly (* $P = 0.024$, * $P = 0.019$, * $P = 0.033$, * $P = 0.010$), while the results




Figure 10. *SERPINH1* promoted the proliferation and viability of HCC cells. (a) Relative expression levels of *SERPINH1* in NC group, si-*SERPINH1* transfection group, *SERPINH1* group and *SERPINH1*+ miR-139-5p transfection group (* $P < 0.05$, compared with NC group). (b) Cell viability of HepG2 cell line was analyzed by MTT assay. (* $P < 0.05$, compared with NC group) (c) Colony numbers were counted and compared between three transfection groups and NC group. The inhibition of *SERPINH1* showed a significant decrease in the number of HepG2 cells. (* $P < 0.05$, compared with NC group) (d) Migration and invasion rate of HepG2 cells in different transfection groups, the migration cells and invasion cells per field suggest the migration and invasion rate of cells. (* $P < 0.05$, compared with NC group) (e) Cell cycle analysis of the cell cycle phase distribution was represented as mean \pm SD (* means $P < 0.05$ compared to NC group). Every experiment was performed for 3 times at least.

showed in *SERPINH1*+ miR-139-5p group were similar with the NC group. In cell cycle assay, we found the HCC cells in the si-*SERPINH1* group were detained in G0/G1 stage, while the overexpression of *SERPINH1* can accelerate the cell cycle of HCC cells (* $P = 0.042$, * $P = 0.031$, Figure 10e).

miR-139-5p can inhibit HCC tumorigenesis in vivo

Transfected efficiency was identified through analyzing the expression levels of miR-139-5p and mRNA *SERPINH1* (*** $P < 0.0001$, ** $P = 0.0057$; * $P = 0.031$, * $P = 0.022$, Figure 11a-B), and results suggested that




Figure 11. *In vivo* assay was used to validate the effects of miR-139-5p and *SNHG6* on tumor growth. (a) Expression levels of miR-139-5p in transfection groups were analyzed to verify the transfection efficiency (** $P < 0.01$, compared with NC group). (b) Relative expression levels of *SERPINH1* in transfection groups were detected by qRT-PCR and western blot. The inhibition of miR-139-5p could significantly induce the expression level of *SERPINH1*. (* $P < 0.05$, compared with NC group) (c) miR-139-5p inhibited HCC cell growth *in vivo*. Tumor growth curve of NC, mimics, miR-139-5p inhibitor, miR-139-5p inhibitor + si-*SNHG6* transfected HepG2 cells in nude mice was shown as mean \pm SD (left panel). The changes in tumor weight among different inoculation groups (right panel). (* $P < 0.05$, ** $P < 0.01$, compared to NC group) (d) Images of the tumors induced by NC, mimics, miR-139-5p inhibitor or miR-139-5p inhibitor+si-*SNHG6* transfected were shown. (e) The conclusion of the regulation relationship among *SNHG6*, miR-139-5p and *SERPINH1*, and their regulation might influence the cell cycle, cell proliferation, cell migration and invasion and further influence the HCC tumorigenesis. Every experiment was performed for 3 times at least.

the overexpression of miR-139-5p can significantly suppress mRNA *SERPINH1* expression, while inhibition of miR-139-5p can significantly induce the level of *SERPINH1* mRNA, which also suggested the transfection was successful. Additionally, the

function of miR-139-5p was validated *in vivo*. The subcutaneous tumors in mouse models were obtained, and the volume and weight of tumors were measured after inoculation, and all the results were shown in Figure 11c. Besides, the inhibition of

miR-139-5p can dramatically increase the tumor volume and weight (** $P = 0.0076$; * $P = 0.029$), while overexpression of miR-139-5p can significantly inhibit the volume and weight of subcutaneous tumors (** $P = 0.0065$; ** $P = 0.046$). The volume and weight of tumor in the inhibitor+si-*SNHG6* group showed no difference from that of the NC group. The images of tumors induced by NC, mimics, inhibitor or inhibitor+si-*SNHG6* were shown in [Figure 11d](#).

By conducting these *in vitro* and *in vivo* experiments, a flowchart was made to estimate the co-expression of *SNHG6* and *SERPINH1* may have a direct target relationship with miR-139-5p. Up-regulation of *SNHG6* in HCC cells could inhibit miR-139-5p expression, and the inhibition of miR-139-5p could further induce *SERPINH1* expression, which could promote the cell proliferation and viability of HCC cells and induce the occurrence and progression of HCC ([Figure 11e](#)).

Discussion

Currently, multiple evidences revealed that lncRNAs are aberrantly expressed in various cancers where they act as tumor suppressors or oncogenes [23,24]. In addition, a novel co-expression network between lncRNAs and mRNAs has been studied, and the regulatory mechanism is predicted to be related to their competition in binding miRNA targets [25,26]. However, the underlying functional mechanism of lncRNAs dysregulation remains to be challenging. In our study, *SNHG6* was selected for comparing the expression level between HCC tissues and cells with normal controls. Based on our results, *SNHG6* was up-regulated in most cases of HCC, which was consistent with the findings from Birgani *et al.* Besides, they also identified that the up-regulated *SNHG6* was related to the poor survival rate of HCC patients with a high possibility[27].

Additionally, the co-expression of *SNHG6* and *SERPINH1* was determined in this study, and the target relationship between miR-139-5p and *SNHG6* was also demonstrated. In many previous studies, *SERPINH1* was reported to be up-regulated in cancers and fibrotic diseases [28,29]. Moreover, it has been suggested that *SERPINH1* expression was

regulated by miR-29a directly in lung cancer cells [15], this finding underlines the close connection between *SERPINH1* dysregulation and lung cancer.

Besides the targeted relationship between miR-139-5p and *SERPINH1*, the regulation of *SNHG6* was critical in controlling the development of HCC. The study of C Cao and T Zhang *et al.* reported that *SNHG6-003* could function as a sponge in HCC and control the expression of miR-26 in HCC tissues [16,30]. Their study stimulated us to figure out the relationship between miR-139-5p and *SERPINH1*, to see if the regulatory control of *SNHG6* to miR-139-5p can provide a further direct regulation on *SERPINH1*. The results of this study demonstrated the tumorigenic roles of *SNHG6* and *SERPINH1* in HCC cells, overexpression of them can induce cell progression both *in vivo* and *in vitro*. Furthermore, the positive regulation between *SNHG6* and *SERPINH1* was revealed.

Over-expression of miR-139-5p was found to suppress the cell migration, invasion and metastasis. According to the research of Wong CC, Wong CM *et al.*, they investigated the expression of miR-139 and identified its significant down-regulation in advanced HCC[31]. Besides, the down-regulation of miR-139 has been reported in several studies in other cancers like head cancer and squamous cell carcinoma [32,33]. However, the biological consequences of the dysregulation of miR-139 in human cancer remain to be characterized. In this study, we identified that the up-regulated *SNHG6* in HCC can directly suppress miR-139-5p expression, the inhibition of miR-139-5p can further target *SERPINH1* expression and accelerate HCC migration and invasion. Further investigations to identify the biological pathway involved in the RNA regulations will enrich our understanding of the regulations of HCC progression. In conclusion, our study has identified a critical anti-metastatic miRNA, miR-139-5p, which was down-regulated in HCC. The positive regulation between *SNHG6* and *SERPINH1* has also been identified in this study. The inhibition of *SNHG6* could induce miR-139-5p expression level in HCC. Overexpression of miR-139-5p could suppress *SERPINH1* expression level and further inhibiting the progression of HCC cells. All the experiment results in this study suggested that *SNHG6* could function as an

oncogene in HCC. The effects of *SNHG6*/miR-139/*SERPINH1* regulation axis on HCC progression had not been investigated before.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was supported by grants from the National Natural Science Foundation of China (Grant No.: 81302161) and the Health and Family Planning Commission of Sichuan Province (Grant No.: 150215).

Ethics approval and consent to participate

This study was authorized by Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, and obtained written informed consents from all the participants.

References

- [1] Choo SP, Tan WL, Goh BK, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. *Cancer*. 2016;122(22):3430–3446.
- [2] Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers*. 2016;2:16018.
- [3] Forner A, Gilabert M, Bruix J, et al. Treatment of intermediate-stage hepatocellular carcinoma. *Nat Rev Clin Oncol*. 2014;11:525–535.
- [4] Nakamoto Y. Promising new strategies for hepatocellular carcinoma. *Hepatol Res*. 2017;47:251–265.
- [5] Zhu J, Liu S, Ye F, et al. The long noncoding RNA expression profile of hepatocellular carcinoma identified by microarray analysis. *PLoS One*. 2014;9:e101707.
- [6] Miranda-Castro R, de-Los-Santos-Alvarez N, Lobo-Castanon MJ. Long noncoding RNAs: from genomic junk to rising stars in the early detection of cancer. *Anal Bioanal Chem*. 2019. DOI:10.1007/s00216-019-01607-6. PMID:30683966
- [7] Huarte M. The emerging role of lncRNAs in cancer. *Nat Med*. 2015;21:1253–1261.
- [8] Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. *Cancer Discov*. 2011;1:391–407.
- [9] Guerrieri F. Long non-coding RNAs era in liver cancer. *World J Hepatol*. 2015;7:1971–1973.
- [10] Chang L, Yuan Y, Li C, et al. Upregulation of *SNHG6* regulates *ZEB1* expression by competitively binding miR-101-3p and interacting with *UPF1* in hepatocellular carcinoma. *Cancer Lett*. 2016;383:183–194.
- [11] Kowalczyk MS, Higgs DR, Gingeras TR. Molecular biology: RNA discrimination. *Nature*. 2012;482:310–311.
- [12] Hua S, Lei L, Deng L, et al. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with *ETS1*. *Oncogene*. 2018;37:1624–1636.
- [13] Zhang L, Dong Y, Zhu N, et al. microRNA-139-5p exerts tumor suppressor function by targeting *NOTCH1* in colorectal cancer. *Mol Cancer*. 2014;13:124.
- [14] Shen K, Liang Q, Xu K, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. *Biochem Pharmacol*. 2012;84:320–330.
- [15] Kamikawaji K, Seki N, Watanabe M, et al. Regulation of *LOXL2* and *SERPINH1* by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis. *J Hum Genet*. 2016;61:985–993.
- [16] Cao C, Zhang T, Zhang D, et al. The long non-coding RNA, *SNHG6-003*, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. *Oncogene*. 2017;36:1112–1122.
- [17] Ito S, Nagata K. Biology of Hsp47 (SerpH1), a collagen-specific molecular chaperone. *Semin Cell Dev Biol*. 2017;62:142–151.
- [18] Kojima T, Miyaishi O, Saga S, et al. The retention of abnormal type I procollagen and correlated expression of HSP 47 in fibroblasts from a patient with lethal osteogenesis imperfecta. *J Pathol*. 1998;184:212–218.
- [19] Naboulsi W, Megger DA, Bracht T, et al. Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma. *J Proteome Res*. 2016;15:38–47.
- [20] Zhu J, Xiong G, Fu H, et al. Chaperone Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene Network. *Cancer Res*. 2015;75:1580–1591.
- [21] Duarte BDP, Bonatto D. The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research. *J Cancer Res Clin Oncol*. 2018;144:2319–2328.
- [22] Zhang X, Ma W, Cui J, et al. Regulation of p21 by *TWIST2* contributes to its tumor-suppressor function in human acute myeloid leukemia. *Oncogene*. 2015;34:3000–3010.
- [23] Chen S, Wu DD, Sang XB, et al. The lncRNA *HULC* functions as an oncogene by targeting *ATG7* and *ITGB1* in epithelial ovarian carcinoma. *Cell Death Dis*. 2017;8:e3118.
- [24] Keckesova Z, Donaher JL, De Cock J, et al. *LACTB* is a tumour suppressor that modulates lipid metabolism and cell state. *Nature*. 2017;543:681–686.
- [25] Liu F, Yuan JH, Huang JF, et al. Long noncoding RNA *FTX* inhibits hepatocellular carcinoma proliferation and metastasis by binding *MCM2* and miR-374a. *Oncogene*. 2016;35:5422–5434.

- [26] Liu XH, Sun M, Nie FQ, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. *Mol Cancer*. 2014;13:92.
- [27] Birgani MT, Hajjari M, Shahrissa A, et al. Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma. *Pathol Oncol Res*. 2018;24:329–337.
- [28] Amenomori M, Mukae H, Sakamoto N, et al. HSP47 in lung fibroblasts is a predictor of survival in fibrotic nonspecific interstitial pneumonia. *Respir Med*. 2010;104:895–901.
- [29] Hirai K, Kikuchi S, Kurita A, et al. Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach. *Anticancer Res*. 2006;26:71–78.
- [30] Tay FC, Lim JK, Zhu H, et al. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. *Adv Drug Deliv Rev*. 2015;81:117–127.
- [31] Wong CC, Wong CM, Tung EK, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. *Gastroenterology*. 2011;140:322–331.
- [32] Liu X, Chen Z, Yu J, et al. MicroRNA profiling and head and neck cancer. *Comp Funct Genomics*. 2009. DOI:10.1155/2009/837514. PMID: 19753298
- [33] Wong TS, Liu XB, Wong BY, et al. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. *Clin Cancer Res*. 2008;14:2588–2592.